...
首页> 外文期刊>Journal of Medicinal Chemistry >Piperazinobenzopyranones and Phenalkylaminobenzopyranones:Potent Inhibitors of Breast Cancer Resistance Protein(ABCG2)
【24h】

Piperazinobenzopyranones and Phenalkylaminobenzopyranones:Potent Inhibitors of Breast Cancer Resistance Protein(ABCG2)

机译:哌嗪基苯并吡喃酮和苯烷基氨基苯并吡喃酮:乳腺癌抗性蛋白(ABCG2)的强抑制剂

获取原文
获取原文并翻译 | 示例

摘要

In continuing research that led us to identify chromanone derivatives(J.Med.Chem.2003,46,2125)as P-glycoprotein inhibitors,we obtained analogues able to modulate multidrug resistance(MDR)mediated by the breast cancer resistance protein(BCRP).The linkage of 5-hydroxybenzopyran-4-one to piperazines or phenalkylamines affords highly potent inhibitors of BCRP.By using sensitive(HCT116)and resistant colon cancer cells expressing BCRP,we evaluated the effect of 14 benzopyranone(chromone)derivatives on the accumulation and the cytotoxic effect of the anticancer drug,mitoxantrone.At 10 muM,three compounds increased both intracellular accumulation and cytotoxicity of mitoxantrone in HCT116/R cells with a comparable rate as fumitremorgin C and Gleevec used as reference inhibitors.The most potent molecules 5b and 5c are still active at 1 muM.,whereas FTC shows weak inhibition.These molecules do not induce cell death as shown by the cell cycle distribution study,which makes them potential candidates for in vivo studies.
机译:在继续的研究中,我们确定了苯并二氢吡喃酮衍生物(J.Med.Chem.2003,46,2125)为P-糖蛋白抑制剂,我们获得了能够调节由乳腺癌抗性蛋白(BCRP)介导的多药抗性(MDR)的类似物。 5-羟基苯并吡喃-4-酮与哌嗪或苯烷基胺的连接提供了强效的BCRP抑制剂。通过使用表达BCRP的敏感(HCT116)和耐药结肠癌细胞,我们评估了14种苯并吡喃酮(色酮)衍生物对积累的影响在10μM时,三种化合物均增加了米托蒽醌在HCT116 / R细胞中的细胞内蓄积和细胞毒性,其作用速度与作为参考抑制剂的fumitremorgin C和Gleevec相当。最有效的分子5b和5b 5c在1μM时仍然有活性,而FTC抑制作用较弱。如细胞周期分布研究所示,这些分子不会诱导细胞死亡,这使其具有潜在的候选资格用于体内研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号